# Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

> **NCT01520103** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 139 (actual)

## Conditions studied

- Her2-negative Metastatic Breast Cancer
- Her2-negative Locally Advanced Breast Cancer

## Interventions

- **DRUG:** Vinorebine, Everolimus
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01520103
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2016-10-31
- **Final completion:** 2016-10-31
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2017-08-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520103, "Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01520103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*